BioMark Diagnostics Inc

Chart & performance

D1W1MN

P/E

—

P/S

870.67

EPS

—

Div yield, %

—

Shrs. gr., 5y

7.47%

Rev. gr., 5y

-10.15%

Revenues

60k

-61.23%

Net income

-1m

L-23.35%

CFO

-1m

L-0.40%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer. These solutions are designed to aid in the identification of the disease, its ongoing monitoring, and the assessment of initial therapeutic interventions. The company has a research partnership with the Icahn School of Medicine, under which they conduct clinical studies concentrating on the early detection of lung cancer. Established in 2014, BioMark Diagnostics Inc. has its main office in Richmond, Canada, and functions as a subsidiary of Biomark Technologies Inc.

URL

https://www.biomarkdiagnostics.com/

IPO date

Nov 03, 2014

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CAD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CAD in thousands, except ratios and share amounts	2026‑03	2025‑03	2024‑03	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT